1993; 16(11):1485–1493.
61 61. Echouffo‐Tcheugui JB et al. Association between prediabetes and risk of chronic kidney disease: a systematic review and meta‐analysis. Diabet Med. 2016; 33(12):1615–1624.
62 62. Dyck PJ et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population‐based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993; 43(4):817–824.
63 63. Putz Z et al. Noninvasive evaluation of neural impairment in subjects with impaired glucose tolerance. Diabetes Care. 2009; 32(1):181–183.
64 64. Grover SA et al. The prevalence of erectile dysfunction in the primary care setting: importance of risk factors for diabetes and vascular disease. Arch Intern Med. 2006; 166(2):213–219.
65 65. Hoffman‐Snyder C et al. Value of the oral glucose tolerance test in the evaluation of chronic idiopathic axonal polyneuropathy. Arch Neurol. 2006; 63(8):1075–1079.
66 66. Nathan DM et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007; 30(3):753–759.
67 67. Barr EL et al. Risk of cardiovascular and all‐cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation. 2007; 116(2):151–157.
68 68. Huang Y et al. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta‐analysis. BMJ. 2016;355: i5953.
69 69. Stacey RB et al. Prediabetes and the association with unrecognized myocardial infarction in the multi‐ethnic study of atherosclerosis. Am Heart J. 2015; 170(5):923–928.
70 70. Brunner EJ et al. Relation between blood glucose and coronary mortality over 33 years in the Whitehall Study. Diabetes Care. 2006; 29(1):26–31.
71 71. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta‐analysis of 102 prospective studies. Lancet. 2010; 375(9733):2215–2222.
72 72. Rao Kondapally Seshasai S et al. Diabetes mellitus, fasting glucose, and risk of cause‐specific death. N Engl J Med. 2011; 364(9):829–841.
73 73. Diabetes Prevention Program Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care. 2002; 25(12):2165–2171.
74 74. Hamman RF et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care. 2006; 29(9):2102–2107.
75 75. Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015; 3(11):866–875.
76 76. Ratner R et al. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care. 2005; 28(4):888–894.
77 77. Florez H et al. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. J Gen Intern Med. 2012; 27(12):1594–1601.
78 78. Diabetes Prevention Program Research Group. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care. 2012; 35(4):723–730.
79 79. Pan XR et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997; 20(4):537–544.
80 80. Gong Q et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30‐year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol. 2019; 7(6):452–461.
81 81. Madsen KS et al. Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev. 2019; 12:CD008558.
82 82. le Roux CW et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet. 2017; 389(10077):1399–1409.
83 83. ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012; 367(4):319–328.
84 84. DeFronzo RA et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011; 364(12):1104–1115.
85 85. The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006; 368(9541):1096–1105.
86 86. Knowler WC et al. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes. 2005; 54(4):1150–1156.
87 87. Torgerson JS et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004; 27(1):155–161.
88 88. Chiasson JL et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP‐NIDDM randomised trial. Lancet. 2002; 359(9323):2072–2077.
89 89. Group NS et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010; 362(16):1477–1490.
90 90. Eriksson JG et al. Long‐term beneficial effects of glipizide treatment on glucose tolerance in subjects with impaired glucose tolerance. J Intern Med. 2006; 259(6):553–560.
91 91. Kanaya AM et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double‐blind, placebo‐controlled trial. Ann Intern Med. 2003; 138(1):1–9.
92 92. Margolis KL et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia. 2004; 47(7):1175–1187.
93 93. Sawicki PT and Kaiser T. Response to Chiasson et al.: Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP‐NIDDM Trial data. Diabetologia. 2004; 47(6):976–977.
94 94. Lindblad U et al. Can sulphonylurea addition to lifestyle changes help to delay diabetes development in subjects with impaired fasting glucose? The Nepi ANtidiabetes StudY (NANSY). Diabetes Obes Metab. 2011; 13(2):185–188.
95 95. Pittas AG et al. Vitamin D supplementation and prevention of type 2 diabetes. N Engl J Med. 2019; 381(6):520–530.
96 96. NAVIGATOR Study Group et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010; 362(16):1463–1476.
97 97. The DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006; 355(15):1551–1562.
98 98. Carlsson LM et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med. 2012; 367(8):695–704.
99 99. Pories WJ et al. Is type II diabetes mellitus (NIDDM) a surgical disease? Ann Surg. 1992; 215(6):633–642; discussion 643.
100 100. Smith AD et al. Physical activity and incident type 2 diabetes mellitus: a systematic review and dose‐response meta‐analysis of prospective cohort studies. Diabetologia. 2016; 59(12):2527–2545.
101 101. Grontved A et al. A prospective study of weight training and risk of type 2 diabetes mellitus in men. Arch Intern Med. 2012; 172(17):1306–1312.
102 102. Salas‐Salvado J et al. Prevention of diabetes with Mediterranean diets: a subgroup analysis of a randomized trial. Ann Intern Med.